Takaomi Saido on Blood NfL Looks Good as Progression and Outcome Marker

COMMENT It is interesting, and appers logical, that NfL levels correlate better with intracellular than with extracellular pathology. saido 0

Charlie Carroll on GeneMatch Registry Recruits Subjects for Prevention Trials

COMMENT I want to say "thanks" to scientists for developing tools that can identify people at greatest risk for the disease, and expedite their recruitment. This is great work. maryjsmith350_213486 0

Kumar Sambamurti on Field Loses Another Pioneer with Passing of Allen Roses, 73

COMMENT Following up on Jeanne's request for reminiscences, I recall that Allen's discussion with song and dance was entertaining and informative. Steve Younkin was there, too. I remember Dale showing a civil war picture and pointing to a gun and statin

Shawn Ferguson on Transport Breakdown Maroons BACE1 in Synapses, Boosts Aβ

COMMENT This study provides interesting new insights into the possible disease relevance of the accumulation of endolysosomal organelles within the dystropic axons that surround amyloid plaques. In a parallel effort, my group has recently identified a distinct JI

A. David Smith on Lancet Commission Claims a Third of Dementia Cases Are Preventable

COMMENT The Lancet Commission report is an heroic achievement but it was rather selective in the risk factors that it reported and which formed the basis of the widely-cited claim that more than a third of dementia cases might be prevented if all the modifiable r

William Rosenblum on Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.

COMMENT Aducanumab may work because it reduces both insouble and soluble Abeta. However it may be incorrect to believe that the beneficial effect can only be manifest in early or prodromal disease because there is too much damage in more advanced cases. Instead i

Jeanne Loring on Treat IBD, Dodge PD? Epidemiology Ties Parkinson’s to Inflammation

COMMENT These findings were was novel to me, and show how the immune system is always surprising us. Systemic inflammation needs to be taken into account when considering cell-based therapy. There are multiple clinical trials planned for treatment of Parkinson’s

Joseph Castellano on Colleagues Mourn Loss of Rahul Desikan, Age 41, to ALS

COMMENT I met Rahul at a conference for early investigators several years back, and we all found it easy to become his colleague and friend. I was struck by his seemingly boundless energy, intelligence, and creativity. It's difficult for me to process the lo

Jürgen Götz on Aducanumab Approved to Treat Alzheimer’s Disease

COMMENT We are watching the approval of aducanumab with interest, given that we had cloned the antibody to evaluate whether a combination with therapeutic ultrasound would be more effective in clearing amyloid and improving cognitive functions in the APP23 mouse

Martin Ingelsson, Dag Sehlin on Double Whammy: APP Uppsala Deletion Ups Aβ and Its Aggregation Propensity

COMMENT We appreciate the insightful comment by Drs. Ezzat and Espay and are grateful that our colleagues noticed an incorrect statement with respect to the MS-based levels of Aβwt1-42, which were indeed lower in mutation carriers as compared to control subjects.

Alzheimer's Disease vs Control: Aβ38 (CSF)

BIOMARKER META ANALYSIS 0.920807786243006 0.85332027485511 0.993632759223626-2.12444191030089 0.0336332086231168 0.780916763617068 0.0174521128326773 Biomarker Comparison Reference:  Biom Comparison: 1690066_1690071 Effect Metric:  0.817187218663974 Lower CI:  0.614198269979088

Control vs Alzheimer's Disease: Aβ38 (CSF)

BIOMARKER META ANALYSIS 1.08600298014432 1.00640804232476 1.17189293336525 2.12444191030089 0.0336332086231168 0.780916763617068 0.0174521128326773 Biomarker Comparison Reference:  Biom Comparison: 1690071_1690066 Effect Metric:  1.22370979031575 Lower CI:  0.919740812144861 Upp

Dementia with Lewy Bodies vs Alzheimer's Disease: Aβ38 (CSF)

BIOMARKER META ANALYSIS 0.714080625729401 0.508804910113144 1.00217417306115-1.9474048722161 0.051486214407545 0.850127262945386 0.07445646234272001 Biomarker Comparison Reference:  Biom Comparison: 1688861_1688856 Effect Metric:  0.471781221994652 Lower CI:  0.339297317850347 U

Frontotemporal Dementia vs Alzheimer's Disease: Aβ38 (CSF)

BIOMARKER META ANALYSIS 0.78371831774872 0.671658195782634 0.914474662010465-3.09561849035528 0.00196402883257577 0.82598138809943 0.0396157854630288 Biomarker Comparison Reference:  Biom Comparison: 1688851_1688841 Effect Metric:  0.633160087276012 Lower CI:  0.535168351646127

MCI-AD vs MCI-Stable: Aβ38 (CSF)

BIOMARKER META ANALYSIS 1.12695137424435 1.02899201804784 1.23423639604187 2.57594602982164 0.009996624843615539 Biomarker Comparison Reference:  Biom Comparison: 1690111_1690116 Effect Metric:  1.07912816902444 Lower CI:  0.939903593097691 Upper CI:  1.23897558614931 LN Effect